Bionxt Solutions Inc. Stock
€0.26
Your prediction
Financial data and news for Bionxt Solutions
sharewise wants to provide you with the best news and tools for Bionxt Solutions, so we directly link to the best financial data sources.
Financials
News
BioNxt Reports Commercialization of ODF Cladribine Product for MS Next Steps
VANCOUVER, BC / ACCESSWIRE / March 18, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to report that based on the recent success of its
BioNxt Reports Successful Results From ODF Cladribine PK Study
VANCOUVER, BC / ACCESSWIRE / March 13, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to report that the comparative pharmacokinetic
BioNxt Reports Completion of ODF Cladribine PK Study
VANCOUVER, BC / ACCESSWIRE / March 4, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to report that the comparative pharmacokinetic
BioNxt Reports Successful Results From ODF Cladribine Toxicity Study
VANCOUVER, BC / ACCESSWIRE / February 8, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to report that the toxicity study for its oral
BioNxt Solutions Announces Completion of Cladribine ODF Toxicity Study and Financing
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
VANCOUVER, BC / ACCESSWIRE / December 22, 2023 / BioNxt Solutions Inc. ("BioNxt" or the "
BioNxt Receives Delivery of Premium Commercial Coating and Cutting Equipment for Commercial Manufacturing of Drug Delivery Products
VANCOUVER, BC / ACCESSWIRE / December 12, 2023 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to announce that it has received delivery of
BioNxt Accelerates Cladribine ODF Clinical and Commercialization Strategy for Multiple Sclerosis Treatment
VANCOUVER, BC / ACCESSWIRE / November 20, 2023 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to provide further details on its clinical and
BioNxt Reports on New Cladrabine ODF Product Development and Commercialization Program
VANCOUVER, BC / ACCESSWIRE / November 15, 2023 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to provide further development details on its
BioNxt Signs Definitive Agreement For 100% Acquisition of IP And Co-Development of Cladribine ODF Drug Reformulation for The Treatment of Multiple Sclerosis
VANCOUVER, BC / ACCESSWIRE / November 13, 2023 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to report that it has signed a definitive
BioNxt Solutions Reports on Barcelona CPHI Conference
VANCOUVER, BC / ACCESSWIRE / November 06, 2023 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to report on a successful CPHI pharma conference